| T.R | Title | User | Personal
Name | Date | Lines |
|---|
| 129.1 | Stock symbol = GLX | EICMFG::AJK | Anton J. Kuchelmeister, @UFC | Fri Mar 27 1992 02:32 | 2 |
| No holder, - but their stock symbol is GLX
|
| 129.2 | | NICCTR::BURTON | CRAY Y-MP EL Product Manager | Fri Mar 27 1992 07:50 | 4 |
| I was considering them about a year ago, but the P/E was too high. Maybe
things have changed now.
Jim
|
| 129.4 | GLX -what is your time horizon? | MCIS1::BONVALLAT | | Fri Mar 27 1992 18:19 | 10 |
|
I'll concur with the last note.
I think Glaxo has been and is an exceptional long-term holding,
but I don't like it short-term.
On the charts, its looking weak, being dragged down in part by
a weakening British stock market.
Its a favorite stock of the portfolio manager of the Janus Twenty fund.
He expects tremendous earnings growth over the next few years. I may
buy GLX myself after (if) we see more correction near-term.
|
| 129.5 | good stuff. | LUDWIG::LOGSDON | | Tue May 05 1992 22:06 | 3 |
| They make great medicine. That maybe a good reason to buy.
Dennis
|
| 129.6 | | EPIK::FINNERTY | The bug stops here | Wed May 06 1992 13:24 | 4 |
|
there's an interesting piece in Barron's this week on Glaxo, Merck,
Syntex, and a few other drug companies. The author felt that they were
now undervalued, and liked Glaxo and Merck in particular.
|
| 129.7 | now? | ZENDIA::FERGUSON | Your recipe is so tasty | Wed Aug 18 1993 11:40 | 12 |
| Revisiting this topic...........
Glaxo rallied yesterday along with other drug company stocks.
it is trading at a near 52-week low...
yesturday: 16 and change...
any comments/speculation on the stock's future performance?
how does the health care issue in Washington play in with this one?
|
| 129.8 | not much! | BROKE::SHAH | Amitabh "Drink DECAF: Commit Sacrilege" | Wed Aug 18 1993 11:58 | 11 |
| Re. .7
> how does the health care issue in Washington play in with this one?
I would suspect not too much. The share of the US operations of
Glaxo's worldwide market is smaller (compared to those of the US-based
pharma. companies).
Glaxo's performance will be determined by what new products they have
in the pipeline and when do the patents on their major drugs like
Zantac expire. (I don't know the answers to either of them.)
|
| 129.9 | | CLARID::JENSEN | | Fri Aug 20 1993 10:18 | 8 |
|
re .-2
It is not only Glaxo which has shown an upward trend. Also Welcome
and Merck have rallied lately. Drug companies in general are now
rated a buy by many brokers.
/Soren
|